DR. ROBERT CLINTON BAST, MD
Medical Practice at Holcombe Blvd, Houston, TX
License number
Texas J6871
Category
Medical Practice
Type
Gynecologic Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-7743
(713) 792-7864 (Fax)
(713) 792-7864 (Fax)
Professional information
Robert Clinton Bast, Houston TX
Specialties:
Oncologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
1400 Pressler St, Houston, TX 77030
1400 Pressler St, Houston, TX 77030
Education:
Harvard Medical School - Doctor of Medicine
Dana-Farber Cancer Institute - Fellowship - Oncology (Internal Medicine)
Brigham & Women's Hospital - Residency - Internal Medicine
Dana-Farber Cancer Institute - Fellowship - Oncology (Internal Medicine)
Brigham & Women's Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Robert C Bast, Houston TX
Specialties:
Internal Medicine, Hematology, Medical Oncology, Gynecologic Oncology, Gynecology, Hematology
Work:
M D Anderson Cancer Ctr
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
Harvard University(1971)
Compositions, Kits, And Methods For Identification, Assessment, Prevention, And Therapy Of Breast Cancer
US Patent:
2003012, Jul 3, 2003
Filed:
Jun 21, 2002
Appl. No.:
10/177293
Inventors:
James Lillie - Natick MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel Meyers - Newton MA, US
Robert Bast - Houston TX, US
Gabriel Hortobagyi - Bellaire TX, US
Lajos Pusztai - Pearland TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon Mills - Houston TX, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel Meyers - Newton MA, US
Robert Bast - Houston TX, US
Gabriel Hortobagyi - Bellaire TX, US
Lajos Pusztai - Pearland TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K039/395, C12Q001/68, G01N033/574, C07H021/04, C12N009/00, C12P021/02, C12N005/06
US Classification:
424/155100, 435/006000, 435/069100, 435/183000, 435/320100, 435/325000, 530/388800, 536/023200, 435/007230
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
Dr. Robert C Bast - MD (Doctor of Medicine)
Hospitals:
Gynecological Oncology Center
1220 Holcombe Blvd STE 1260, Houston 77030
Gynecological Oncology Center
1220 Holcombe Blvd STE 1260, Houston 77030
1220 Holcombe Blvd STE 1260, Houston 77030
Gynecological Oncology Center
1220 Holcombe Blvd STE 1260, Houston 77030
Education:
Medical Schools
Harvard Medical School
Graduated: 1971
Harvard Medical School
Graduated: 1971
Novel Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
US Patent:
2007019, Aug 16, 2007
Filed:
Dec 6, 2006
Appl. No.:
11/634620
Inventors:
Natalia Iartchouk - Wayland MA, US
Mark Ayers - Pennington NJ, US
Jeffrey Brown - Arlington MA, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Gordon Mills - Houston TX, US
Mark Ayers - Pennington NJ, US
Jeffrey Brown - Arlington MA, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Gordon Mills - Houston TX, US
Assignee:
MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68, G01N 33/574, C12N 5/06, C07K 16/30
US Classification:
435006000, 435007230, 435338000, 530388800
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
Biomarkers For The Detection Of Early Stage Ovarian Cancer
US Patent:
2014003, Feb 6, 2014
Filed:
Jun 3, 2013
Appl. No.:
13/909022
Inventors:
Robert Bast - Houston TX, US
Kevin Coombes - Houston TX, US
Kevin Coombes - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
Vermillion, Inc. - Austin TX
Vermillion, Inc. - Austin TX
International Classification:
G01N 33/574
US Classification:
506 9, 506 12, 506 18, 506 16
Abstract:
The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples.
Biomaker For Ovarian And Endometrial Cancer: Hepcidin
US Patent:
2010006, Mar 18, 2010
Filed:
Mar 9, 2009
Appl. No.:
12/381218
Inventors:
Eric T. Fung - Los Altos CA, US
Robert Bast - Houston TX, US
Daniel W. Chan - Clarksville MD, US
Jin Song - Baltimore MD, US
Valdimir Podust - Fremont CA, US
Zhen Zhang - Dayton MD, US
Robert Bast - Houston TX, US
Daniel W. Chan - Clarksville MD, US
Jin Song - Baltimore MD, US
Valdimir Podust - Fremont CA, US
Zhen Zhang - Dayton MD, US
Assignee:
Vermilllion, Inc. - Fremont CA
The Johns Hopkins University - Baltimore MD
Board of Regents, The University of Texas System - Austin TX
The Johns Hopkins University - Baltimore MD
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 33/53, G01N 33/543
US Classification:
435 71, 436518
Abstract:
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
Nucleic Acid Molecules And Proteins For The Identification, Assessment, Prevention, And Therapy Of Ovarian Cancer
US Patent:
2005021, Sep 29, 2005
Filed:
Feb 4, 2005
Appl. No.:
11/050926
Inventors:
John Monahan - Walpole MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrissey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natik MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrissey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natik MA, US
Assignee:
MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
C12Q001/68, G01N033/574
US Classification:
435006000, 435007230
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
Biomarker For Ovarian And Endometrial Cancer: Hepcidin
US Patent:
7510842, Mar 31, 2009
Filed:
Mar 10, 2006
Appl. No.:
11/373833
Inventors:
Valdimir Podust - Fremont CA, US
Zhen Zhang - Dayton MD, US
Eric T. Fung - Los Altos CA, US
Robert Bast - Houston TX, US
Daniel W. Chan - Clarksville MD, US
Jin Song - Baltimore MD, US
Zhen Zhang - Dayton MD, US
Eric T. Fung - Los Altos CA, US
Robert Bast - Houston TX, US
Daniel W. Chan - Clarksville MD, US
Jin Song - Baltimore MD, US
Assignee:
Vermilllion, Inc. - Fremont CA
The John Hopkins University - Baltimore MD
Board of Regents, The University of Texas System - Austin TX
The John Hopkins University - Baltimore MD
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 33/53
US Classification:
435 71, 435 723
Abstract:
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
Nucleic Acid Molecules And Proteins For The Identification, Assessment, Prevention, And Therapy Of Ovarian Cancer
US Patent:
2003008, May 8, 2003
Filed:
Mar 14, 2002
Appl. No.:
10/097340
Inventors:
John Monahan - Walpole MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrisey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natick MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrisey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natick MA, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q001/68, G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.